Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280038 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL30275188 | 0.83 | CTSL (0.41) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL15095805 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL4404331 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL2095210 | 0.78 | NPC1 (0.67) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL20794233 | 0.77 | MEP1B (0.49) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL12169920 | 0.75 | MMP13 (0.51) | SMN1; SMN2ALDH1A1HTTRAB9ANPC1 | |
| SCHEMBL578205 | 0.73 | HRH3 (0.56) | SMN1; SMN2ALDH1A1PYCR1 | |
| SCHEMBL8825194 | 0.73 | CYP4F2 (0.58) | SMN1; SMN2ALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL516523 | 0.70 | ADRB2 (0.48) | ALDH1A1HTTKMT2ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794163-B1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER (US) | 2009-12-23 | — | — | EP | claimed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | claimed |
| EP-1794163-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | Pfizer, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | claimed |
| EP-1794163-B1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1794163-B1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1794163-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | Pfizer, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | PARP1, PARP11, PARP2 | SMN1; SMN2 1016/4885ALDH1A1 1028/4885HTT 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.